Table of Contents

company-logo

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Dividend Announcement

• Cyclerion Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Cyclerion Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Cyclerion Therapeutics Dividend History

Cyclerion Therapeutics Dividend Yield

Cyclerion Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Cyclerion Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Cyclerion Therapeutics Financial Ratios

P/E ratio-0.69
PEG ratio0.01
P/B ratio0.45
ROE-55.31%
Payout ratio0.00%
Current ratio5.07
Quick ratio5.07
Cash Ratio4.10

Cyclerion Therapeutics Dividend FAQ

Does Cyclerion Therapeutics stock pay dividends?
Cyclerion Therapeutics does not currently pay dividends to its shareholders.
Has Cyclerion Therapeutics ever paid a dividend?
No, Cyclerion Therapeutics has no a history of paying dividends to its shareholders. Cyclerion Therapeutics is not known for its dividend payments.
Why doesn't Cyclerion Therapeutics pay dividends?
There are several potential reasons why Cyclerion Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Cyclerion Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Cyclerion Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Cyclerion Therapeutics a dividend aristocrat?
Cyclerion Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Cyclerion Therapeutics a dividend king?
Cyclerion Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Cyclerion Therapeutics a dividend stock?
No, Cyclerion Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Cyclerion Therapeutics stocks?
To buy Cyclerion Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Cyclerion Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.